PT  - JOURNAL ARTICLE
AU  - Alexandra D. Dreyfuss
AU  - Paco E. Bravo
AU  - Constantinos Koumenis
AU  - Bonnie Ky
TI  - Precision Cardio-Oncology
AID  - 10.2967/jnumed.118.220137
DP  - 2019 Apr 01
TA  - Journal of Nuclear Medicine
PG  - 443--450
VI  - 60
IP  - 4
4099  - http://jnm.snmjournals.org/content/60/4/443.short
4100  - http://jnm.snmjournals.org/content/60/4/443.full
SO  - J Nucl Med2019 Apr 01; 60
AB  - Modern oncologic therapies and care have resulted in a growing population of cancer survivors with comorbid, chronic health conditions. As an example, many survivors have an increased risk of cardiovascular complications secondary to cardiotoxic systemic and radiation therapies. In response, the field of cardio-oncology has emerged as an integral component of oncologic patient care, committed to the early diagnosis and treatment of adverse cardiac events. However, as current clinical management of cancer therapy–related cardiovascular disease remains limited by a lack of phenotypic data, implementation of precision medicine approaches has become a focal point for deep phenotyping strategies. In particular, -omics approaches (a field of study in biology ending in -omic, such as genomics, proteomics, or metabolomics) have shown enormous potential in identifying sensitive biomarkers of cardiovascular disease, applying sophisticated, pattern-revealing technologies to growing databases of biologic molecules. Moreover, the use of -omics to inform radiologic strategies may add a dimension to future clinical practices. In this review, we present a paradigm for a precision medicine approach to the care of cardiotoxin-exposed cancer patients. We discuss the role of current imaging techniques; demonstrate how -omics can advance our understanding of disease phenotypes; and describe how molecular imaging can be integrated to personalize surveillance and therapeutics, ultimately reducing cardiovascular morbidity and mortality in cancer patients and survivors.